Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss

Peter Diamond, Agatha Labrinidis, Sally K. Martin, Amanda N. Farrugia, Stan Gronthos, L. Bik To, Nobutaka Fujii, Peter D. O'Loughlin, Andreas Evdokiou, Andrew C W Zannettino

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)-mediated skeletal destruction. We have previously shown that elevated plasma levels of PC-derived CXCL12 are associated with presence of X-ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and βCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OC-mediated bone resorption was identified. To confirm the OC-activating potential of MM PC-derived CXCL12 in vivo, we established a model of MM-mediated focal osteolysis, wherein MM PC lines, such as RPMI-8226, were injected into the tibias of nude mice. Implanting RPMI-8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5% decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist Tl40. Furthermore, implanting CXCL12-overexpressing RPMI-8226 cells resulted in a 13% decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions.

LanguageEnglish
Pages1150-1161
Number of pages12
JournalJournal of Bone and Mineral Research
Volume24
Issue number7
DOIs
Publication statusPublished - 1 Jul 2009

Keywords

  • CXCL12
  • Multiple myeloma
  • Osteolysis
  • Stromal-derived factor-1α

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Diamond, Peter ; Labrinidis, Agatha ; Martin, Sally K. ; Farrugia, Amanda N. ; Gronthos, Stan ; To, L. Bik ; Fujii, Nobutaka ; O'Loughlin, Peter D. ; Evdokiou, Andreas ; Zannettino, Andrew C W. / Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. In: Journal of Bone and Mineral Research. 2009 ; Vol. 24, No. 7. pp. 1150-1161.
@article{7805341e06744d84a6c41f05ff565660,
title = "Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss",
abstract = "The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)-mediated skeletal destruction. We have previously shown that elevated plasma levels of PC-derived CXCL12 are associated with presence of X-ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and βCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OC-mediated bone resorption was identified. To confirm the OC-activating potential of MM PC-derived CXCL12 in vivo, we established a model of MM-mediated focal osteolysis, wherein MM PC lines, such as RPMI-8226, were injected into the tibias of nude mice. Implanting RPMI-8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5{\%} decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist Tl40. Furthermore, implanting CXCL12-overexpressing RPMI-8226 cells resulted in a 13{\%} decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions.",
keywords = "CXCL12, Multiple myeloma, Osteolysis, Stromal-derived factor-1α",
author = "Peter Diamond and Agatha Labrinidis and Martin, {Sally K.} and Farrugia, {Amanda N.} and Stan Gronthos and To, {L. Bik} and Nobutaka Fujii and O'Loughlin, {Peter D.} and Andreas Evdokiou and Zannettino, {Andrew C W}",
year = "2009",
month = "7",
day = "1",
doi = "10.1359/jbmr.090210",
language = "English",
volume = "24",
pages = "1150--1161",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "7",

}

Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. / Diamond, Peter; Labrinidis, Agatha; Martin, Sally K.; Farrugia, Amanda N.; Gronthos, Stan; To, L. Bik; Fujii, Nobutaka; O'Loughlin, Peter D.; Evdokiou, Andreas; Zannettino, Andrew C W.

In: Journal of Bone and Mineral Research, Vol. 24, No. 7, 01.07.2009, p. 1150-1161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss

AU - Diamond, Peter

AU - Labrinidis, Agatha

AU - Martin, Sally K.

AU - Farrugia, Amanda N.

AU - Gronthos, Stan

AU - To, L. Bik

AU - Fujii, Nobutaka

AU - O'Loughlin, Peter D.

AU - Evdokiou, Andreas

AU - Zannettino, Andrew C W

PY - 2009/7/1

Y1 - 2009/7/1

N2 - The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)-mediated skeletal destruction. We have previously shown that elevated plasma levels of PC-derived CXCL12 are associated with presence of X-ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and βCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OC-mediated bone resorption was identified. To confirm the OC-activating potential of MM PC-derived CXCL12 in vivo, we established a model of MM-mediated focal osteolysis, wherein MM PC lines, such as RPMI-8226, were injected into the tibias of nude mice. Implanting RPMI-8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5% decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist Tl40. Furthermore, implanting CXCL12-overexpressing RPMI-8226 cells resulted in a 13% decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions.

AB - The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)-mediated skeletal destruction. We have previously shown that elevated plasma levels of PC-derived CXCL12 are associated with presence of X-ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and βCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OC-mediated bone resorption was identified. To confirm the OC-activating potential of MM PC-derived CXCL12 in vivo, we established a model of MM-mediated focal osteolysis, wherein MM PC lines, such as RPMI-8226, were injected into the tibias of nude mice. Implanting RPMI-8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5% decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist Tl40. Furthermore, implanting CXCL12-overexpressing RPMI-8226 cells resulted in a 13% decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions.

KW - CXCL12

KW - Multiple myeloma

KW - Osteolysis

KW - Stromal-derived factor-1α

UR - http://www.scopus.com/inward/record.url?scp=70349150575&partnerID=8YFLogxK

U2 - 10.1359/jbmr.090210

DO - 10.1359/jbmr.090210

M3 - Article

VL - 24

SP - 1150

EP - 1161

JO - Journal of Bone and Mineral Research

T2 - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 7

ER -